This strongly supports the clinical relevance of HMGA2 as a potential novel predictive biomarker of metastasis and therapeutic resistance in CRC, which also warrants further study as a potential target for personalized therapeutic intervention. Here, HMGA2 is linked to colorectal carcinoma.